Printed From BioPortfolio.com

Maxhealth to Distribute Legacy's Hair Loss Treatment in China

23:49 EDT 27 Oct 2017 | ChinaBio Today

Maxhealth Medicine of Wuxi, China struck a deal with Switzerland's Legacy Healthcare to commercialize Legacy's CG 210 in Mainland China and Macao. CG210 is a botanical treatment for hair loss that has been shown to slow the rate of hair loss. Legacy develops innovative patentable botanical drugs in oncology supportive care and dermatology. Maxhealth, which commercializes drugs and medical devices in China, made an investment in Legacy, though financial details were not disclosed. More details....

Share this with colleagues:

Original Article: Maxhealth to Distribute Legacy's Hair Loss Treatment in China

More From BioPortfolio on "Maxhealth to Distribute Legacy's Hair Loss Treatment in China"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cancer
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches